Beckman jumps through regulatory hoops for Biositeas IMI bides time at the sidelines
This article was originally published in Clinica
Despite having cleared US and German anti-trust authorities without a hitch, and with its tender for all Biosite shares set to expire this week, Beckman Coulter may yet find itself far from the finishing line in its proposed $1.55bn acquisition of the San Diego, California-based diagnostics company.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.